Search research articles
Contact Us
Filters
Showing results (21-30 of 36) with videos related to
Page
of 4
Sort By:
Endoscopy
|
August 1, 1993
Small cell carcinoma of the esophagus in a cirrhotic patient
P Deplaix, O Dumas, C Barthélémy, et al.
Journal of Viral Hepatitis
|
October 6, 2015
Serum miR-122 may serve as a biomarker for response to direct acting antivirals: effect of paritaprevir/R with dasabuvir or ombitasvir on miR-122 in HCV-infected subjects
J F Waring, E O Dumas, S Abel, et al.
Plos One
|
June 1, 2018
Reduced ITPase activity and favorable IL28B genetic variant protect against ribavirin-induced anemia in interferon-free regimens
Aparna Vasanthakumar, Justin W Davis, Manal Abunimeh, et al.
Occupational and Environmental Medicine
|
April 26, 2011
Under-estimation of self-reported occupational exposure by questionnaire in hospital workers
C Donnay, M-A Denis, R Magis, et al.
Clinical Pharmacokinetics
|
February 20, 2016
Drug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers
Akshanth R Polepally, Jennifer R King, Bifeng Ding, et al.
Occupational and Environmental Medicine
|
August 28, 2016
Development of a job-task-exposure matrix to assess occupational exposure to disinfectants among US nurses
C Quinot, O Dumas, P K Henneberger, et al.
Antimicrobial Agents and Chemotherapy
|
March 8, 2017
Paritaprevir and Ritonavir Liver Concentrations in Rats as Assessed by Different Liver Sampling Techniques
Charles S Venuto, Marianthi Markatou, Yvonne Woolwine-Cunningham, et al.
The European Respiratory Journal
|
October 2, 2010
Do young adults with childhood asthma avoid occupational exposures at first hire?
O Dumas, L A M Smit, I Pin, et al.
The Lancet. Gastroenterology & Hepatology
|
April 19, 2017
Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial
Tania M Welzel, Tarik Asselah, Emily O Dumas, et al.
The International Journal on Drug Policy
|
February 9, 2019
Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy
Jason Grebely, Gregory J Dore, Negar N Alami, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 36) with videos related to
Sort By:
Page
of 4
Endoscopy
|
August 1, 1993
Small cell carcinoma of the esophagus in a cirrhotic patient
P Deplaix, O Dumas, C Barthélémy, et al.
Journal of Viral Hepatitis
|
October 6, 2015
Serum miR-122 may serve as a biomarker for response to direct acting antivirals: effect of paritaprevir/R with dasabuvir or ombitasvir on miR-122 in HCV-infected subjects
J F Waring, E O Dumas, S Abel, et al.
Plos One
|
June 1, 2018
Reduced ITPase activity and favorable IL28B genetic variant protect against ribavirin-induced anemia in interferon-free regimens
Aparna Vasanthakumar, Justin W Davis, Manal Abunimeh, et al.
Occupational and Environmental Medicine
|
April 26, 2011
Under-estimation of self-reported occupational exposure by questionnaire in hospital workers
C Donnay, M-A Denis, R Magis, et al.
Clinical Pharmacokinetics
|
February 20, 2016
Drug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers
Akshanth R Polepally, Jennifer R King, Bifeng Ding, et al.
Occupational and Environmental Medicine
|
August 28, 2016
Development of a job-task-exposure matrix to assess occupational exposure to disinfectants among US nurses
C Quinot, O Dumas, P K Henneberger, et al.
Antimicrobial Agents and Chemotherapy
|
March 8, 2017
Paritaprevir and Ritonavir Liver Concentrations in Rats as Assessed by Different Liver Sampling Techniques
Charles S Venuto, Marianthi Markatou, Yvonne Woolwine-Cunningham, et al.
The European Respiratory Journal
|
October 2, 2010
Do young adults with childhood asthma avoid occupational exposures at first hire?
O Dumas, L A M Smit, I Pin, et al.
The Lancet. Gastroenterology & Hepatology
|
April 19, 2017
Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial
Tania M Welzel, Tarik Asselah, Emily O Dumas, et al.
The International Journal on Drug Policy
|
February 9, 2019
Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy
Jason Grebely, Gregory J Dore, Negar N Alami, et al.
Page
of 4